Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Skin Cancer01:30

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Five-year survival with tebentafusp in metastatic uveal melanoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

Uveal melanoma: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up.

ESMO open·2026
Same author

Montelukast as a novel therapeutic approach in metastatic uveal melanoma harboring a CYSLTR2 mutation: a translational case report.

ESMO open·2025
Same author

Evaluation of Sézary cell marker expression and cell death behaviour upon in vitro treatment by flow cytometry in Sézary syndrome patients.

Experimental dermatology·2024
Same author

Treatment-specific evaluation of the modified Glasgow-Prognostic-Score in patients with advanced cutaneous melanoma.

Journal of the European Academy of Dermatology and Venereology : JEADV·2021
Same author

[Brain metastases-Interdisciplinary approach towards a personalized treatment].

Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen·2021

Related Experiment Video

Updated: May 14, 2026

A 3D Organotypic Melanoma Spheroid Skin Model
08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

[Personalized therapy concepts for malignant melanoma].

M Schlaak1, N Kreuzberg, C Mauch

  • 1Klinik für Dermatologie und Venerologie, Hauttumorzentrum im CIO Köln-Bonn, Uniklinik Köln, Kerpener Str. 62, 50937, Köln.

Der Internist
|February 2, 2013
PubMed
Summary

Metastatic melanoma treatment has advanced significantly with targeted therapies and immunotherapy. These novel approaches, including BRAF inhibitors and immune checkpoint inhibitors, offer life-prolonging options for patients.

More Related Videos

Unveiling Therapeutic Opportunities with Melanoma Patient-derived Organoid Models
05:33

Unveiling Therapeutic Opportunities with Melanoma Patient-derived Organoid Models

Published on: September 6, 2024

A Melanoma Patient-Derived Xenograft Model
07:07

A Melanoma Patient-Derived Xenograft Model

Published on: May 20, 2019

Related Experiment Videos

Last Updated: May 14, 2026

A 3D Organotypic Melanoma Spheroid Skin Model
08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

Unveiling Therapeutic Opportunities with Melanoma Patient-derived Organoid Models
05:33

Unveiling Therapeutic Opportunities with Melanoma Patient-derived Organoid Models

Published on: September 6, 2024

A Melanoma Patient-Derived Xenograft Model
07:07

A Melanoma Patient-Derived Xenograft Model

Published on: May 20, 2019

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunology

Context:

  • Metastatic melanoma remains a challenging cancer with limited effective systemic therapies prior to 2011.
  • Cytotoxic chemotherapy offered limited response rates in a small patient subgroup.
  • Advances in understanding melanoma's molecular pathology have identified key mutations for targeted treatment.

Purpose:

  • To review the advancements in systemic therapy for metastatic melanoma.
  • To highlight the impact of molecular profiling and immunotherapy on treatment strategies.
  • To discuss novel therapeutic targets and their clinical implications.

Summary:

  • Activating mutations in the BRAF gene, found in approximately 50% of melanomas, are targets for specific inhibitors.
  • Mutations in c-Kit and NRAS also present opportunities for targeted therapies.
  • Immunotherapy, including CTLA-4 blockade and PD-1/PD-L1 targeting, activates cytotoxic T cells to combat melanoma.

Impact:

  • For the first time, life-prolonging systemic therapies are available for metastatic melanoma patients.
  • Targeted therapies and immunotherapy represent a paradigm shift in melanoma treatment.
  • These advancements offer improved survival outcomes and new hope for patients with advanced melanoma.